Minipigs represent a good animal model because of the physiologic and anatomic similarities they share with humans. Three cytochrome P450 (CYP) 3A isozymes, CYP3A22, CYP3A29, and CYP3A46, have recently been reported to be expressed in Bama minipigs, which have limited data relating to their metabolic characteristics. In the present study, Bama minipig CYP3A22, CYP3A29, and CYP3A46 were recombinantly expressed and their metabolic manners were compared with those of human CYP3A4 and CYP3A5 and also human and Bama minipig liver microsomes. The results indicated Bama minipigs and human CYP3A enzymes showed similar metabolic kinetics and metabolite profiles using testosterone, midazolam, and nifedipine as substrates. However, the differences in amino acid sequences change the elimination velocity and metabolic preference of CYP3A enzymes to their substrates. It was demonstrated that CYP3A29, CYP3A4, and CYP3A5 were the most active enzymes for all reactions, whereas CYP3A46 was the least active enzyme. Substrate-dependent metabolism characteristics between human and Bama minipig CYP3A isoenzymes exist.
Introduction
Animal models are used in preclinical studies to predict the kinetics and toxicity of drugs in humans. However, the extrapolation of animal data to humans is often difficult because of species differences, which may lead to failure of candidate drugs during the clinical research process (Lin, 1995; Friedberg, 2000) . An increasing number of studies suggest that minipigs may serve as suitable models for human pharmacological studies because of their physiologic and anatomic similarities to humans (Bode et al., 2010; Puccinelli et al., 2011) . Previous studies have shown that all primary activities of human cytochrome P450 (CYP) enzymes are found in minipig CYP enzymes (Bode et al., 2010; Puccinelli et al., 2011) . Similar CYP3A activities were observed in minipig and human liver microsomes when testing specific substrates (Anzenbacher et al., 1998; Bogaards et al., 2000; Zuber et al., 2002; Turpeinen et al., 2007) . For this reason, the minipig is thought to be a good experimental model for drug metabolism mediated by human CYP3A. However, previous data are mostly from minipig microsomes, which represent a complex mixture of multiple enzymes. Data relating to pure minipig CYP3A isoforms are limited. Therefore, it is necessary to compare the catalytic specificities of minipig and human CYP3A enzymes.
CYP3A is considered the most important CYP subfamily, comprising approximately 30% of total human hepatic CYP and responsible for nearly 50% of clinical drug metabolisms (Wang et al., 2012) . There are four CYP3A isoforms expressed in humans: CYP3A4, CYP3A5, CYP3A7, and CYP3A43. CYP3A4 and CYP3A5 are the predominant CYP3A enzymes expressed in the human liver and are responsible for most CYP3A-mediated drug metabolism (Daly, 2006) . CYP3A7 is mainly expressed in the fetal liver. Both CYP3A7 and CYP3A43 are expressed at low levels in the adult liver. In our recent study, we identified three CYP3A isozymes expressed in Bama minipigs: CYP3A22 (GenBank accession number KJ636082), CYP3A29 (GenBank accession number EU918131), and CYP3A46 (GenBank accession number NM_001134824.1) (Shang et al., 2009 (Shang et al., , 2013 . CYP3A29 was the first sequenced and cloned porcine CYP3A and was previously thought to be the CYP3A4-like isoform found in minipigs (Nissen et al., 1998; Anzenbacherova et al., 2005; Yao et al., 2011) . However, our results showed that CYP3A22 and CYP3A46 are the most highly expressed isoforms in the Bama minipig liver (Shang et al., 2013) . Human and Bama minipig CYP3A show a high homology, sharing 73.8-76.8% identities and 83.3-85.7% positives (Shang et al., 2009 (Shang et al., , 2013 .
In the present study, three pure Bama minipig CYP3A isoforms, CYP3A22, CYP3A29, and CYP3A46, as well as two human CYP3A isoforms, CYP3A4 and CYP3A5, were expressed using the Bac-toBac baculovirus expression system in Sf9 cells, a widely used expression system for enzyme protein expression of mammalian cells. A previous analysis has suggested that CYP3A4 has multiple probe substrates due to distinct CYP3A4-binding domains for each substrate subgroup (Kenworthy et al., 1999; Galetin et al., 2003) . Usually, testosterone, midazolam, and nifedipine are selected as well known substrates of CYP3A4 (Katoh et al., 2001; Thörn et al., 2011) . In this study, we further investigated the metabolic similarities and differences between Bama minipig and human recombinant CYP3A enzymes as well as their liver microsomes.
Materials and Methods
Materials. See Supplemental Materials and Methods. Heterologous Expression of Human and Bama Minipig CYP3A Enzymes in Sf9 Cells. The polymerase chain reaction primers were designed for introducing restriction sites and a histidine tag (His6) (see Supplemental Materials and Methods). All polymerase chain reaction products were verified by DNA sequencing and subcloned into the donor vector pFastbac1. The recombinant CYP3A4, CYP3A5, CYP3A22, CYP3A29, and CYP3A46 baculovirus were generated using a Bac-to-Bac baculovirus expression system according to the manufacturer's manual (Invitrogen, Carlsbad, CA). All steps for the production of recombinant enzymes were carried out as in our previous methods Chen et al., 2012; Yu et al., 2013) . Sf9 cells suspended in Gibco Sf900II medium were coinfected with a virus encoding CYP3A enzymes, cytochrome P450 oxidoreductase and cytochrome b5 gene, at a ratio of 3:3:1. The total protein concentration was measured by bicinchoninic acid assay, and the content of cytochrome P450 was measured using the carbon monoxide (CO)-difference spectrum according to the method described previously (Guengerich et al., 2009) .
Kinetic Assay. Testosterone 6b-hydroxylation, midazolam 19-hydroxylation, and nifedipine oxidation are considered the specific reactions mediated by CYP3A in humans. Therefore, testosterone, midazolam, and nifedipine were chosen as substrates to compare the metabolic abilities between Bama minipig CYP3A22, CYP3A29, and CYP3A46 and human CYP3A4 and CYP3A5. Incubation mixtures of CYP3A enzymes with testosterone (2021000 mM), midazolam (1250 mM), or nifedipine (22200 mM) were in 100-ml final volumes (100 mM Tris-HCl, pH 7.4, 15 mM MgCl 2 , and NADPH generating system). The final concentration of organic solvent (methanol) in the incubation mixture was less than 0.5% (v/v). Pooled human liver microsomes (HLMs) with a protein concentration of 20 mg/ml (n = 3; Lot number DDND, YOBL, and VYIA) were purchased from the Research Institute for Liver Diseases (Shanghai, China). The pig liver microsomes (PLMs) were prepared with the ultracentrifugation methods from three Bama minipigs (Zhou et al., 2001 ). The P450 content of HLM and PLM was 110 and 88 pmol/mg protein, respectively. Substrates were incubated with 0.3 mg protein/ml HLM and PLM.
All incubations were performed in triplicate under the linear conditions determined previously (data not shown) under optimized incubation times (15260 minutes) and protein concentrations (0.120.5 mg/ml). The samples were preincubated for 2 minutes at 37°C in a shaking water bath. The reactions were initiated by the addition of 1 mM NADPH/NADP and terminated with 400 ml of methanol containing loratadine as an internal standard (final concentration of 10 mg/ml). Samples were centrifuged at 14,000g for 15 minutes to precipitate proteins and membranes. Ten microliter aliquots of the supernatants were injected into high-performance liquid chromatography (HPLC)-tandem mass spectrometry for analysis (the HPLC-tandem mass spectrometry method and the method validation results can be seen in the Supplemental Materials and Methods).
Metabolite Profiles by HPLC. Metabolite profiles of testosterone, midazolam, and nifedipine catalyzed by recombinant CYP3A enzymes and liver microsomes were determined by an Agilent 1200 HPLC system (Palo Alto, CA) equipped with a binary solvent delivery pump, column oven, UV detector, and autosampler. Chromatographic separation was performed on a ZORBAX BONUS-RP column (4.6 Â 150 mm, 5 mm; Agilent) at 30°C. Metabolites of testosterone were analyzed by UV detection at 245 nm, with the isocratic mobile phase of 37% water and 63% methanol at a flow rate of 1 ml/min. Metabolites of midazolam were analyzed by UV detection at 220 nm, with the isocratic mobile phase of 63% water containing 0.05 mM ammonium acetate and 37% acetonitrile at a flow rate of 1 ml/min. Metabolites of nifedipine were analyzed by UV detection at 223 nm, with the isocratic mobile phase of 57% water and 43% acetonitrile at a flow rate of 1 ml/min.
Chemical Inhibition Assay. A range of concentrations of ketoconazole (0.0225 mM for testosterone, 0.00521 mM for midazolam, and 0.0225 mM for nifedipine) were added in the incubation mixtures with 10 pmol/ml CYP3A enzymes. As for the liver microsomes assay, a concentration of ketoconazole (0.0125 mM for testosterone, 0.00525 mM for midazolam, and 0.0125 mM for nifedipine) was adjusted in the mixtures with 0.3 mg protein/ml. All incubations were performed with optimized incubation times and substrate concentrations (near the S 50 values of human and Bama minipig CYP3A enzymes and liver microsomes). The production of 6b-hydroxytestosterone, 19-hydroxymidazolam, and oxidized nifedipine was used as the evaluation factor for the inhibitory effect.
Results and Discussion
Expression of Human and Bama Minipig CYP3A Enzymes in Sf9 Cells. All recombinant CYP3A enzymes registered a single band at approximately 55 kDa, according to a western blot assay (Supplemental Fig. 1 ). Total P450 was measured using the COdifference spectrum, which produced a specificity spectrum of cytochrome P450, with a maximum wavelength of 450 nm. The P450 content of recombinant CYP3A4, CYP3A5, CYP3A22, CYP3A29, and CYP3A46 was 123, 181, 156, 142, and 241 pmol/mg protein, respectively.
Kinetic Properties and Chemical Inhibition Assay. Reaction rates were measured according to the production of metabolites (6b-hydroxytestosterone, 19-hydroxymidazolam, and oxidized nifedipine). The categories of kinetic profiles of testosterone 6b-hydroxylation, midazolam 19-hydroxylation, and nifedipine oxidation by recombinant Bama minipig and human CYP3A enzymes and liver microsomes were at first evaluated using the Eadie-Hofstee analysis, which indicated that not all of the reactions fitted the classic MichaelisMenten model (Supplemental Fig. 2) . Therefore, kinetic parameters were calculated by the Hill equation and the results are shown in Table 1 (Houston and Kenworthy, 2000) . Both on pooled liver microsomes and recombinant enzymes levels, the kinetic parameters of the three reactions showed significantly differences. However, considering that most V max and S 50 values had an order of magnitude, we also thought humans and minipigs had similarities in CYP3A metabolic characteristics to some extent. Kinetic analysis of testosterone 6b-hydroxylation revealed a nonlinear Eadie-Hofstee plot for CYP3A4, CYP3A5, and CYP3A46 and a linear plot for CYP3A22 and CYP3A29 (Supplemental Fig. 2A) . Combined with the results of the microsomal incubation, human liver microsomes and recombinant enzymes have a similar metabolic behavior. Although the similarity between Bama minipig liver microsomes and CYP3A22 and CYP3A29 suggested testosterone might be mainly metabolized by CYP3A22 and CYP3A29 in the Bama minipig, the Hill coefficients were 1.23, 1.48, and 1.23 for CYP3A4, CYP3A5, and CYP3A46, respectively, indicating a positive cooperativity. This cooperativity, however, is abolished in CYP3A22 and CYP3A29. The intrinsic clearance (CL int ) values of midazolam 19-hydroxylation catalyzed by human CYP3A enzymes were dramatically higher than those catalyzed by the Bama minipig. Midazolam 19-hydroxylation between CYP3A5 and CYP3A22 and nifedipine oxidation between CYP3A5 and CYP3A22 or CYP3A29 seemed to have no obvious differences in the S 50 values. Since the liver microsomes are kind of mixture enzymes, it makes no sense to compare V max between liver microsomes and recombinant enzymes. However, the S 50 values are relatively close.
All of the kinetic features for recombinant enzymes and liver microsomes cannot be explained with the classic Michaelis-Menten model, requiring characteristic curved Eadie-Hofstee plots to identify such behavior. Testosterone, metabolized by human recombinant CYP3A4/5 enzymes and human liver microsomes, and nifedipine, metabolized by human CYP3A5 and minipig CYP3A29 and 3A46, displayed autoactivation kinetics consistent with previous reports (Houston and Kenworthy, 2000; Hutzler and Tracy, 2002 CYP3A29 and human CYP3A4 and CYP3A5 were the most active enzymes for testosterone 6b-hydroxylation, midazolam 19-hydroxylation, and nifedipine oxidation, respectively, whereas Bama minipig CYP3A46 was the least active for all reactions.
The results of the present study had some differences as compared with a previous study, which compared the substrate kinetics of pig CYP3A29 and human CYP3A4 (Yao et al., 2011) . The differences in kinetic parameters are likely due to differences between pig breeds, the source of recombinant enzymes, and the cytochrome P450 assay used. In the present study, each recombinant CYP3A was expressed in our laboratory under optimized conditions and coexpressed with the same amount of CYP oxidoreductase and cytochrome-b5 reductase, respectively. The total cytochrome P450 in recombinant enzymes was measured according to the procedure published in Nature Protocols, which optimizes and standardizes the measurement of cytochrome P450 (Guengerich et al., 2009) , whereas the recombinant CYP3A4 and CYP3A29 from the previous study were derived from different sources using an older method of measuring cytochrome P450 (Omura and Sato, 1964) . The kinetic values for testosterone 6b-hydroxylation, midazolam 19-hydroxylation, and nifedipine oxidation derived from our recombinant CYP3A4/5 are in accordance with the data provided by the U.S. Food and Drug Administration (http:// www.fda.gov/Drugs/DevelopmentApprovalProcess/DevelopmentResources/ DrugInteractionsLabeling/ucm080499.htm), reinforcing that the data derived from recombinant Bama minipig and human CYP3A enzymes in the present study are reliable.
Apparent K i values of ketoconazole for human and Bama minipig CYP3A enzymes and their liver microsomes are listed in Table 2 using a nonlinear regression analysis. The results indicated that the selective inhibitor ketoconazole is capable of inhibiting the catalytic activities of human and Bama minipig CYP3A enzymes. The apparent K i values of ketoconazole against the three probe substrates were all in the range of three times when comparing Bama minipig CYP3A22/29/ 46 with human CYP3A4/5. Considering the high homology and similar metabolite profiles between human and minipig CYP3As, we supposed a similar mode of inhibition in the effect of ketoconazole on human and minipig CYP3As, which should be confirmed in future studies.
Metabolite Profiles. The chromatograms for testosterone, midazolam, and nifedipine incubated with recombinant CYP3A enzymes and liver microsomes are presented in Fig. 1 . Three major metabolites of testosterone were generated from the incubation of human and Bama minipig recombinant CYP3A enzymes and liver microsomes (Fig. 1A) . The most abundant metabolite was identified as 6b-hydroxytestosterone, and the other two were inferred to be 1b-hydroxytestosterone (M2) and 2b-hydroxytestosterone (M3), according to previously published data (Krauser et al., 2004) . The production of M2 and M3 was much less than that of 6b-hydroxytestosterone when catalyzed by both Bama minipig and human CYP3A enzymes. The peak of M2 was comparable with M3 in the samples catalyzed by human CYP3A4 and CYP3A5 and liver microsomes. The production of M2, however, was greater than that of M3 when metabolized by Bama minipig CYP3A29 and CYP3A46, but less than that of M3 catalyzed by Bama minipig CYP3A22 and liver microsomes, 1B. The production of 19-hydroxymidazolam was greater than that of M4 during incubation with the CYP3A enzymes, except in the case of Bama minipig CYP3A22 and its liver microsomes. These results show that midazolam metabolized by Bama minipig CYP3A22 is prone to generate M4. As shown in Fig. 1C , only one observed metabolite, 
